What 3 Receptors Does Retatrutide Affect?

Retatrutide affects three receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-receptor profile distinguishes it from currently authorised medicines in the same class. Each receptor plays a distinct role in regulating appetite, insulin secretion, liver glucose output, and energy expenditure. Retatrutide holds no marketing authorisation in the UK or elsewhere and is available only within authorised clinical trials. This article explains what each receptor does, what trial data have found, and what the current regulatory position is.

Which three receptors does retatrutide target and what do they do?

Retatrutide targets the GLP-1, GIP, and glucagon receptors. GLP-1 reduces appetite and stimulates insulin release, GIP enhances insulin secretion, and the glucagon receptor regulates liver glucose output and energy expenditure.

Retatrutide targets three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-receptor profile distinguishes it from currently authorised medicines in the same class. GLP-1 receptors are found in the pancreas, gut, brain and heart, and their activation promotes insulin secretion, slows gastric emptying and reduces appetite.^[8][12] GIP receptors, also present in the pancreas and adipose tissue, enhance insulin release in a glucose-dependent manner and may influence fat metabolism.^[9][10] The glucagon receptor, expressed primarily in the liver, regulates glucose output and plays a role in energy expenditure and fat breakdown.^[1][2]

By engaging all three receptors simultaneously, retatrutide acts across overlapping but complementary metabolic pathways. GLP-1 and GIP receptor agonism together form the basis of tirzepatide (Mounjaro), which is already MHRA-authorised in the UK for type 2 diabetes and chronic weight management.^[5][6] Retatrutide adds glucagon receptor agonism to this dual mechanism. Based on preclinical studies and early-phase human pharmacology data, researchers hypothesise that this additional receptor engagement may further increase energy expenditure and enhance fat oxidation beyond what dual agonism alone achieves; however, the extent to which this translates to meaningful clinical benefit in humans is still being established in ongoing Phase 3 trials.

It is important to note that retatrutide holds no marketing authorisation in the UK or anywhere else. It is available only within authorised clinical trials. The information here is educational, based on published trial data, and does not constitute a recommendation or a pathway to obtaining the medicine.

How does activating GLP-1, GIP, and glucagon receptors affect the body?

Activating all three receptors together reduces appetite, stimulates glucose-dependent insulin secretion, and increases energy expenditure, while glucagon receptor agonism also promotes fat breakdown and raises liver glucose output.

Activating GLP-1, GIP, and glucagon receptors together produces coordinated effects on appetite, insulin secretion, liver glucose output, and energy expenditure. Each receptor contributes a distinct physiological action, and their combined stimulation is intended to address multiple aspects of metabolic dysfunction at once.

GLP-1 receptor activation reduces appetite by acting on satiety centres in the hypothalamus and brainstem, slows the rate at which food leaves the stomach, and stimulates insulin release from pancreatic beta cells in a glucose-dependent manner, meaning insulin is only released when blood glucose is elevated. This glucose-dependency is an important safety feature, as it reduces the risk of hypoglycaemia compared with some older antidiabetic agents. However, based on experience with the broader incretin-based therapy class, hypoglycaemia risk can increase when these medicines are used alongside insulin or sulfonylureas in diabetes management; anyone taking such combinations should discuss this with their diabetes care team.^[13]

GIP receptor activation complements GLP-1 by further enhancing glucose-stimulated insulin secretion and may also support glucagon suppression after meals. There is also evidence from preclinical and early clinical research that GIP receptor agonism influences adipose tissue metabolism, though the precise human mechanisms remain an active area of investigation.

Glucagon receptor agonism adds a third layer of metabolic effect. Glucagon is a hormone that normally raises blood glucose by stimulating the liver to release stored glucose (glycogenolysis) and produce new glucose (gluconeogenesis). In the context of retatrutide, glucagon receptor activation is thought to increase energy expenditure and promote fat breakdown (lipolysis), potentially contributing to weight reduction. However, because glucagon also raises blood glucose, the net metabolic effect depends on the balance between all three receptor actions working together. Researchers are still characterising how this balance plays out across different patient populations.

What did clinical trials find about retatrutide's triple-receptor mechanism?

Phase 2 trials published in the New England Journal of Medicine in 2023 showed mean body weight reductions of approximately 17 to 24 per cent at the highest doses; Phase 3 TRANSCEND and TRIUMPH programmes have reported clinically meaningful reductions in HbA1c and body weight.

Clinical trial findings on retatrutide's triple-receptor mechanism span Phase 2 and, more recently, Phase 3 studies. The Phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled adults with obesity (with or without type 2 diabetes) and assessed retatrutide at multiple doses over 48 weeks. Participants receiving the highest doses studied showed mean body weight reductions of approximately 17 to 24 per cent compared with placebo, alongside improvements in fasting glucose, insulin sensitivity and lipid profiles. A separate Phase 2 trial in people with type 2 diabetes demonstrated reductions in HbA1c of approximately 2 percentage points at higher doses, alongside body weight loss.^[2] Researchers noted that the glucagon receptor component appeared to contribute to increased energy expenditure, though separating the individual contributions of each receptor in a human trial is methodologically complex.

Phase 3 data are now available from the TRANSCEND and TRIUMPH programmes. The TRANSCEND-T2D-1 study, which evaluated retatrutide in adults with type 2 diabetes, has reported results including clinically meaningful reductions in HbA1c and body weight; full peer-reviewed publication of these findings should be consulted for precise figures and confidence intervals.^[3][4] Results from the TRIUMPH trials (evaluating retatrutide in adults with obesity) have been presented at major diabetes and obesity congresses, with topline data indicating substantial weight reduction at the doses studied. These Phase 3 readouts represent a more robust evidence base than Phase 2 alone, though the complete dataset across all trials in both programmes is still being compiled and reviewed.

It is essential to interpret all these results in context. Trial populations, doses, and follow-up durations vary, and no cross-trial comparisons should be drawn. No conclusions about what an individual might experience can be drawn from trial-level data. Retatrutide remains available only within authorised clinical trials, and no regulatory authority has yet granted a marketing authorisation.

What are the known and potential side effects linked to this mechanism?

The most commonly reported side effects in retatrutide trials are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, consistent with the GLP-1 class; glucagon receptor activation introduces additional considerations around transient glucose changes and liver effects.

The side effects observed in retatrutide trials are broadly consistent with those seen across the GLP-1 receptor agonist class, with some additional considerations arising from glucagon receptor activation. In the Phase 2 trials, the most commonly reported adverse effects were gastrointestinal in nature:

• Nausea, particularly during dose escalation

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects are thought to result primarily from GLP-1 and GIP receptor activation slowing gastric motility and acting on central appetite pathways. They were generally dose-dependent and tended to diminish over time, though they led to treatment discontinuation in a proportion of participants.

Glucagon receptor agonism introduces additional theoretical considerations. Because glucagon raises blood glucose, there is a potential for transient increases in fasting glucose, particularly at higher doses or during early treatment. In the trial populations studied, the net effect on blood glucose was a reduction, suggesting the insulin-stimulating actions of GLP-1 and GIP outweighed the glucagon-mediated glucose-raising effect. However, the long-term implications of sustained glucagon receptor stimulation, including effects on the liver and cardiovascular system, require further characterisation in larger, longer trials.

As with other medicines in this class, pancreatitis has been reported as a concern to monitor. Anyone experiencing severe and persistent abdominal pain should seek prompt medical assessment via their GP or, if symptoms are severe, contact NHS 111 for urgent advice.

Gallbladder and biliary disease is a recognised risk with GLP-1 and GIP-based therapies as a class.^[15][16] Symptoms that warrant prompt medical assessment include pain in the upper right abdomen, fever, and yellowing of the skin or eyes (jaundice). Anyone experiencing these symptoms should contact their GP or NHS 111 without delay.

Participants enrolled in a retatrutide clinical trial should report any adverse events to the trial team in accordance with the study protocol. If urgent or emergency medical care is needed, participants should inform the treating clinician that they are enrolled in a clinical trial and, where possible, present their study identification card so that the care team is aware of the investigational medicine.

Healthcare professionals and trial participants who wish to report a suspected adverse reaction to a medicine outside the trial reporting process may do so through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

What is retatrutide's current regulatory status in the UK?

Retatrutide has no marketing authorisation from the MHRA or any other regulatory body worldwide, and it cannot be prescribed or supplied outside an authorised clinical trial.

Retatrutide does not hold a marketing authorisation in the UK, and it has not been authorised by any regulatory body worldwide. In the UK, medicines are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Until the MHRA grants a marketing authorisation following a full review of safety, efficacy and quality data, retatrutide cannot be prescribed or supplied outside an authorised clinical trial. No timeline for a potential application or authorisation can be given.

NICE (the National Institute for Health and Care Excellence) recommends medicines for NHS use in England following MHRA authorisation. NICE has not reviewed retatrutide, and NHS availability cannot be assumed or predicted at this stage. Commissioning decisions for any future licensed treatment would ultimately rest with Integrated Care Boards (ICBs), not with NICE alone.

Anyone who encounters retatrutide being sold online, offered through a clinic, or described as available for purchase should be aware that such a product cannot be a licensed medicine and may be falsified or counterfeit. Purchasing unlicensed or unverified injectable medicines carries serious health risks.

For people interested in evidence-based weight management options that are currently available, licensed treatments do exist and can be discussed with a GP or a qualified healthcare professional. Retatrutide's scientific profile is of genuine research interest, but its place in clinical practice, if any, will only be established after the full Phase 3 programme is reviewed by regulators and a marketing authorisation is granted.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff AM et al.).
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes (Rosenstock J et al.).
3. Efficacy and safety of retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in type 2 diabetes (Bajaj HS et al.) – The Lancet.
4. Efficacy and safety of retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in type 2 diabetes (Bajaj HS et al.) – PubMed record.
5. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
6. Tirzepatide for managing overweight and obesity (TA1026).
7. Tirzepatide | Drugs | BNF – NICE.
8. Semaglutide | Drugs | BNF – NICE.
9. GIP biology and fat metabolism (Yip RG et al.).
10. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nature Reviews Endocrinology.
11. Physiological roles of the GIP receptor in murine brown adipose tissue. Molecular Metabolism.
12. Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clinical Medicine Insights: Endocrinology and Diabetes.
13. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion (Christensen AS et al.).
14. EU actions to tackle shortages of GLP-1 receptor agonists. European Medicines Agency.
15. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (He L et al.). JAMA Internal Medicine.
16. GLP-1 receptor agonists and gallbladder disease risk (Ramírez-Mejía MM et al.).
17. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology.
18. Clinical trials for medicines: apply for authorisation in the UK. MHRA/GOV.UK.
19. About technology appraisal guidance. NICE.
20. Introducing new medicines in the NHS in the UK – pathway. GOV.UK.
21. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide. Nephrology Dialysis Transplantation.

Frequently Asked Questions